Status:
WITHDRAWN
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Heroin Dependence
Opioid-Related Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the abuse liability and reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in heroin-dependent volunteers
Detailed Description
not available at this time
Eligibility Criteria
Inclusion Criteria:
Individuals must be at least 18 yrs of age, currently opioid dependent and must not be seeking treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use.
Exclusion Criteria:
Individuals with evidence of an active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.
Key Trial Info
Start Date :
October 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 1999
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000330
Start Date
October 1 1999
End Date
November 1 1999
Last Update
May 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Health Sciences Center
Denver, Colorado, United States, 80206